VERICEL CORPORATION Current Liabilities
VERICEL CORPORATION (VCEL) had Current Liabilities of $52.53 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $52.53M.
- 2026-03-31: Liabilities, Current $47.16M.
- 2025-12-31: Liabilities, Current $49.15M.
- 2025-09-30: Liabilities, Current $45.58M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $52.53M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $47.16M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $49.15M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $45.58M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $41.13M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $39.45M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $50.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | $41.35M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $43.86M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $36.47M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $45.75M 10-K · filed 2025-02-27 |
| 2023-09-30 | $35.95M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $35.61M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $28.75M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $37.46M 10-K · filed 2024-02-29 |
| 2022-09-30 | $27.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $25.01M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $21.73M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $26.05M 10-K · filed 2023-02-23 |
| 2021-09-30 | $18.83M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $23.86M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $23.23M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $22.48M 10-K · filed 2022-02-24 |
| 2020-09-30 | $21.31M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $18.12M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $18.13M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $19.80M 10-K · filed 2021-02-24 |
| 2019-09-30 | $15.11M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $12.54M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $12.94M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $14.79M 10-K · filed 2020-02-25 |
| 2018-09-30 | $14.99M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $15.22M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $13.88M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $13.09M 10-K · filed 2019-02-26 |
| 2017-09-30 | $14.53M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $12.94M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $14.75M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $12.85M 10-K · filed 2018-03-05 |
| 2016-09-30 | $15.36M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $11.46M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $13.77M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $12.11M 10-K · filed 2017-03-13 |
| 2015-09-30 | $9.26M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $10.82M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $12.62M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $11.83M 10-K · filed 2016-03-14 |
| 2014-09-30 | $12.48M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $17.05M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $6.11M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $5.32M 10-K · filed 2015-03-25 |
| 2013-09-30 | $7.25M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $3.84M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $4.28M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $5.66M 10-K · filed 2014-03-13 |
| 2012-09-30 | $6.98M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $11.99M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $22.35M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $20.67M 10-K · filed 2013-03-18 |
| 2011-09-30 | $25.18M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $30.42M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $29.86M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |